Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5289 |
Name | uterus leiomyosarcoma |
Definition | A uterine Corpus sarcoma and leiomyosarcoma and uterine Corpus smooth muscle neoplasm that is located_in the smooth muscle of the uterus. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer uterine corpus cancer uterine corpus sarcoma uterus leiomyosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR1 over exp | PD173074 | uterus leiomyosarcoma | sensitive | detail... |
FGFR1 over exp | Fexagratinib | uterus leiomyosarcoma | sensitive | detail... |
FGFR1 over exp | Infigratinib | uterus leiomyosarcoma | sensitive | detail... |
FGFR1 positive | PD173074 | uterus leiomyosarcoma | decreased response | detail... |
FGFR1 positive | Fexagratinib | uterus leiomyosarcoma | decreased response | detail... |
FGFR1 positive | Infigratinib | uterus leiomyosarcoma | decreased response | detail... |
RAD51B del | Olaparib + Temozolomide | uterus leiomyosarcoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02203760 | Phase II | Pazopanib Gemcitabine + Pazopanib | Pazopanib vs. Pazopanib Plus Gemcitabine (PazoDoble) | Active, not recruiting | DEU | 0 |
NCT02428192 | Phase II | Nivolumab | Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma | Active, not recruiting | USA | 0 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
NCT03241745 | Phase II | Nivolumab | A Study of Nivolumab in Selected Uterine Cancer Patients | Completed | USA | 0 |
NCT03548428 | Phase II | Atezolizumab | Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Stereosarc) | Recruiting | FRA | 0 |
NCT03880019 | Phase II | Olaparib + Temozolomide | Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma | Active, not recruiting | USA | 0 |
NCT03926936 | Phase II | Fulvestrant | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (FUCHSia) | Completed | NLD | BEL | 0 |
NCT04028063 | Phase II | Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT04200443 | Phase II | Cabozantinib + Temozolomide | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04969887 | Phase II | Ipilimumab + Nivolumab | Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) | Active, not recruiting | NZL | AUS | 0 |
NCT05432791 | Phase II | Pazopanib Olaparib + Temozolomide Trabectedin | Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working | Active, not recruiting | USA | 1 |
NCT05649956 | Phase II | Letrozole | Letrozole in Uterine Leiomyosarcoma | Recruiting | USA | 0 |